Advertisement


Bradley J. Monk, MD, on Cervical Cancer: Findings on Pembrolizumab Plus Chemotherapy

2023 ASCO Annual Meeting

Advertisement

Bradley J. Monk, MD, of the University of Arizona, Phoenix, and Creighton University, discusses phase III findings from the KEYNOTE-826 study of overall survival results in patients with persistent, recurrent, or metastatic cervical cancer. Study participants received first-line treatment of pembrolizumab plus chemotherapy, with or without bevacizumab, which reduced the risk of death by up to 40% in three different subsets of patients (Abstract 5500).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
I'd like to share with you my perspective about the treatment of women with recurrent metastatic or persistent cervical cancer. This is a group of patients that we call as the first line treatment. Now, this is a very serious problem. This is the number four cause of cancer death worldwide, and in this country, it causes more than 4,000 deaths. So historically, the treatment has been doublet chemotherapy, platinum, and taxane. And then in 2014, we added bevacizumab to it with a small improvement in overall survival of only three to four months. And here we've sat, since 2014, chemotherapy with or without bevacizumab. Now, immune therapy is everywhere. It got a very limited conditional approval in the second line in 2018, but we wanted to move it to the first line with chemotherapy, with or without bevacizumab. So on behalf of the 151 sites in 19 countries, I'd like to share with you the results of Keynote 826, which randomized 617 patients one-to-one, chemotherapy with or without bevacizumab, to pembrolizumab or placebo. And that trial led to FDA approval in October 2021, but it was an interim result. It was very preliminary, and now I'd like to share with you the final result. And the final result is that when pembrolizumab is added to chemotherapy versus placebo, there was a 40% improvement in overall survival. What does that mean? That means they live a year longer. A terminal disease that now, average age of 50, live a year longer. And we might even be curing some patients. It's too early to tell. But this is a two-year treatment, six doses of chemotherapy, and then two years of total immune therapy. And then at three years, a third of the patients are now without progression and a year without treatment. There is a plateau, 30% of the patients or so. So this is a major step forward. This confirms two things. Number one, that the preliminary result is real with a year improvement overall survival. And second, that pembrolizumab is best used in the front line rather than in the second line. And these are patients who have PD-L1 high expressing tumors according to the 22C3 antibody CPS greater than equal to one, which is 89% of the patients. So this is an opportunity for almost all patients with first line cervical cancer to add pembrolizumab to chemotherapy with or without bevacizumab at the discretion of their provider.

Related Videos

Issues in Oncology

Carmen E. Guerra, MD, MSCE, on Diversity, Equity, and Inclusion in Clinical Trials: Expert Commentary

Carmen E. Guerra, MD, MSCE, of the University of Pennsylvania Abramson Cancer Center, discusses three key abstracts presented at ASCO: strategies to increase accrual of underrepresented populations in Alliance NCTN trials, how patient-clinician education can strengthen partnerships and improve diversity in breast and lung cancer trials, and mediators of racial and ethnic inequities in clinical trial participation among U.S. patients with cancer from 2011 to 2022 (Abstracts 6509, 6510, 6511).

Lung Cancer
Immunotherapy

Jonathan W. Riess, MD, on EGFR-Mutated Non–Small Cell Lung Cancer: What’s Next?

Jonathan W. Riess, MD, of the University of California, Davis Comprehensive Cancer Center, explores the findings of three important clinical trials in lung cancer treatment: whether to incorporate immune checkpoint inhibitors into the treatment of EGFR-mutated lung cancer, the importance of central nervous system activity in EGFR-mutant lung cancer, and new therapies for disease with EGFR exon 20 insertion.

Colorectal Cancer

Cathy Eng, MD, and Lars Henrik Jensen, MD, PhD, on Locally Advanced Colon Cancer: Efficacy of Neoadjuvant Chemotherapy and Standard Treatment

Cathy Eng, MD, of Vanderbilt-Ingram Cancer Center, and Lars Henrik Jensen, MD, PhD, of the Danish Colorectal Cancer Center South and the University Hospital of Southern Denmark, discuss phase III results from the Scandinavian NeoCol trial, which showed that neoadjuvant chemotherapy is not superior to standard upfront surgery in terms of disease-free and overall survival in patients with colon cancer, although there are certain circumstances when this approach may have more favorable outcomes (Abstract LBA3503).

Lymphoma

Tycel J. Phillips, MD, and Alex F. Herrera, MD, on Classical Hodgkin Lymphoma: New Data on Nivolumab, AVD, and Brentuximab Vedotin

Tycel J. Phillips, MD, and Alex F. Herrera, MD, both of the City of Hope National Medical Center, discuss results from the SWOG S1826 study, which showed that nivolumab and AVD (doxorubicin, vinblastine, and dacarbazine) improved progression-free survival vs brentuximab vedotin plus AVD in patients with advanced-stage classical Hodgkin lymphoma. Longer follow-up is needed to assess overall survival and patient-reported outcomes. This trial may be a key step toward harmonizing the pediatric and adult treatment of advanced-stage disease (LBA4).

Lung Cancer

Narjust Florez, MD, and Filippo Gustavo Dall’Olio, MD, on NSCLC: New Findings on Tumor Fraction, Durvalumab, and Survival

Narjust Florez, MD, of Dana-Farber Cancer Institute, and Filippo Gustavo Dall’Olio, MD, of Institut Gustave Roussy, discuss circulating tumor DNA tumor fraction, and its link to survival in patients with advanced non–small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial. Tumor fraction was positive in 16% of patients randomly assigned to receive durvalumab in the study. This population seems to have a limited benefit from maintenance durvalumab after induction chemotherapy (Abstract 2516).

Advertisement

Advertisement




Advertisement